Ostalo
METABOLIC DISORDERS IN RENAL TRANSPLANT RECIPIENTS
IVANA MIKOLAŠEVIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
ITA JELIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
BRANKA SLADOJE-MARTINOVIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
LIDIJA ORLIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
STELA ŽIVčIć-ćOSIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
SRETENKA VUKSANOVIć-MIKULIčIć
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
MAJA MIJIć
; Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
SANJIN RAčKI
; Klinički bolnički centar Rijeka, Medicinski fakultet Sveučilišta u Rijeci, Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Rijeka,Hrvatska
Sažetak
Introduction: Advancements in immunosuppressive treatment of renal transplant recipients have signiicantly increased the graft and patient survival and signiicantly lowered the incidence of rejection crises. Efforts to increase long term patient and graft survival are directed to the prevention and treatment of cardiovascular diseases because they are the leading cause of mortality in these patients. Traditional risk factors for the development of cardiovascular diseases (e.g., arterial hypertension, posttransplant diabetes mellitus and metabolic lipid disorder) are up to ifty times more frequent among renal transplant recipients than in the general population. The goal of this study was to analyze the prevalence of the above mentioned metabolic disorders in renal transplant recipients, to analyze the impact of immunosuppressive therapy on the manifestation of these mentioned metabolic disorders, and to analyze the antihypertensive therapy applied. Subjects and Methods: We analyzed 53 patients that underwent renal transplantation at Rijeka University Hospital Center during
a two-year follow-up. Glomerulonephritis was the primary kidney disease in 14 (29.6%), polycystic kidney disease in 10 (18.87%), interstitial nephritis in 7 (13.21%), nephroangiosclerosis in 5 (18.5%), diabetic nephropathy in 4 (7.55%) and other diseases in 13
(24.53%) patients. Results: The study included 53 patients (58.5% male), mean age 49.8±11.3 (range 27-72) years and mean dialysis treatment before transplantation 56.0±41.9 months. All patients received triple immunosuppressive therapy including a calcineurin inhibitor/ MMF/corticosteroids and induction with IL-2 receptor blocker (daclizumab or basiliximab). Thirty-three (62%) patients were treated with tacrolimus and 20 (38%) with cyclosporine. The mean creatinine value was 144.92±46.49. Eighteen (34%) patients had creatinine lower than 120 mmol/L and 35 (66%) patients had a level higher than 120 mmol/L. After transplantation, 49 (92.5%) patients were treated for arterial hypertension (arterial hypertension was deined as systolic blood pressure greater than 140 mm Hg and diastolic pressure greater than 90 mm Hg or the routine use of antihypertensive therapy). Patients receiving cyclosporine had a signiicantly higher incidence of arterial hypertension as compared with patients on tacrolimus (P=0.025). Among patients with serum creatinine level higher than 120 mmol/L, 32 (65.3%) patients had hypertension, 9 (17%) achieved target blood pressure (<130/80 mm Hg), 8 (16.32%) were treated with one drug, 24 (48.98%) with two drugs, 15 (30.61%) with three drugs and 2 (4.09%) with more than three antihypertensives. Only four patients did not take any antihypertensive medication. The most often used antihypertensive drugs were calcium channel blockers (40.4% of patients), β-blockers (26.6%), and RAS inhibitors (9.2% of atients received ACE inhibitors and 16.5% ARB). In 6 (11.3%) patients, posttransplant diabetes mellitus developed and 21 (39.62%) patients were treated for metabolic lipid disorder. Conclusion: In order to identify patients at a higher risk of developing cardiovascular disease with time, it is essential that kidney transplant recipients undergo regular follow up of graft function, blood pressure, and metabolic parameters. Good graft function is important to improve the quality of life and decrease mortality of renal transplant recipients.
Ključne riječi
cardiovascular diseases; diabetes mellitus; dyslipidemias; hypertension; kidney transplantation
Hrčak ID:
97576
URI
Datum izdavanja:
14.2.2013.
Posjeta: 1.956 *